Sessions
How to Market my Biotech to Investors: Lessons Learned from Successful Investment and Funding Rounds
Workforce of the Future: Talent, Change Management and Enabling Future Development
Delivering Projects and Managing Timelines in the Variable, Continuously Changing Environment Of Cell and Gene Therapy
Patient and Payer Challenges: Enabling Access to Patients through Market Access, Pricing and Patient-Led Discussion
Moving the Industry Towards Automated Systems for Scale-up Success
Tech Review: New Platforms and Closed-Systems to Enable Commercial Success
Working With a CDMO is not Just an Outsourcing Contract but a Partnership: Learnings from Successful Biotech/CDMO Partnerships
Overcoming Challenges and Setting Up for Success on the Path to Commercialisation
How to Market my Biotech to Investors: Lessons Learned from Successful Investment and Funding Rounds
09:00 Chairperson’s Opening
Bryan Poltilove, Operational Partner, Broadoak Capital Partners
09:05 Accelerating Cures – Translating stem cell discoveries into therapies
- Early stage funds to de-risk and commercialize stem cell technologies
- What investors look for
Amritha Jaishankar, Executive Director, Maryland Stem Cell Research Fund (MSCRF)
09:20 Incubators, Accelerators and “Hackathons” – What Investors Need to Know
- Defining terms: Incubators, Accelerators, and Hackathons
- What is the investor value of Incubators, Accelerators, and Hackathons?
- How to differentiate between Incubators and Accelerators that add value, or just collect checks , equity, and PR.
Louis Walcer, Director, The Kevin M. McGovern Family Center for Venture Development in Life Sciences, Cornell University
09:35 A Startup Owners Manual: Rejection, Persistence, and Success in Financing
- Investor dating: how to find the right partner and what they are looking for
- Building for a big vision and creating positive signaling along the way
- Practice makes perfect: being persistent and dealing with rejection
Brian Feth, Co-Founder and Chief Executive Officer, Xcell Biosciences
09:50 Taking A Drug Product beyond Phase 2 With Multiple Investment Rounds
- An early IPO, pros and cons
- Handling expectations
Mathias Svahn, Chief Executive Officer and Co-Founder, NextCell Pharma
10:05 Speaker Q&A and Panel Discussion
Joined by all session speakers
Speakers
Louis Walcer
Director, The Kevin M. McGovern Family Center for Venture Development in the Life Sciences
